CVS Pays $315 Million to Settle DOJ Opioid Dispensing Lawsuit

By Grace Kim

CVS Pharmacy Inc. and its subsidiaries will pay $315 million to resolve a Justice Department lawsuit alleging the company unlawfully dispensed medically unnecessary prescriptions of highly addictive opioids, officials said Tuesday.

The deal closes a case the DOJ filed in 2024 under President Joe Biden's administration. The lawsuit accused CVS of violating the Controlled Substances Act by prescribing massive amounts of opioids and other controlled substances "to fuel its own profits at the expense of public health and safety."

The complaint gets specific. It alleged CVS filled illegitimate prescriptions for high doses of potent opioids that "fed dependence and addiction," many of them originating from known "pill mills" — providers that hand out prescriptions without a legitimate medical purpose. Those prescriptions were often billed to and reimbursed by Medicaid and other federal healthcare programs, the lawsuit says.

What does the settlement require beyond the payment?

Money isn't the only term. Under the agreement, CVS must also "implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate," Assistant Attorney General Brett Shumate, who leads the Justice Department's Civil Division, said in a statement.

Associate Attorney General Stanley Woodward framed the deal as part of a broader federal push. "Today's settlement is a significant milestone in the Justice Department's efforts to combat the opioid epidemic by cracking down on pharmacies who unlawfully fulfill prescriptions for controlled substances," Woodward said in an emailed statement.

The DOJ's case rested on more than bad prescriptions. It alleged that poor staffing levels, combined with performance metrics and incentive compensation policies CVS implemented, pushed pharmacists to race through prescriptions without confirming they were legitimate.

How did CVS respond?

CVS isn't admitting fault. The company said it strongly disagreed with the claims and that the settlement admits no wrongdoing.

In a statement, CVS said its pharmacists were trained "in the safe and appropriate use of all medications" and that it had implemented "best-in-class" programs to help them "make the best decisions on behalf of patients."

The company has pushed back on the regulatory framework before. In 2024, CVS said pharmacists were being held to "vague, undefined, and ever-changing standards of practice" when it comes to filling prescription opioids.

In short: CVS is paying $315 million while maintaining it did nothing wrong.

How big is the opioid litigation bill for corporate America?

Very. Over the last decade, drugmakers, wholesalers, pharmacies and other companies have agreed to settlements with U.S. governments totaling over $50 billion.

Most of that money is intended to address the addiction and overdose crisis, which has been linked to more than 100,000 U.S. deaths in some years — though the numbers have fallen sharply recently.

The majority of settlements — and dollars — have come from state and local governments. But the federal government has struck several deals of its own, including agreements in the last two years with the pharmacies Walgreens and Walmart.

The CVS settlement extends that pattern into 2025, and the new compliance safeguards mean the company's dispensing operations will stay under federal expectations long after the $315 million check clears.